Using gray-market versions of Lilly’s triple-G leads to relatively poor weight loss, study finds

Eli Lilly’s triple agonist retatrutide appears to be the most effective obesity drug to have reached late-stage trials, with weight loss of up to 25% in Phase 3. This has led growing ...